XFOR (X4 Pharmaceuticals) Moat Score: 4/10 (As of Jun. 25, 2026)


XFOR X4 Pharmaceuticals Inc XFOR
29 GF Score
Price $3.97
! 7 Warning Signs
View Full Analysis

What is X4 Pharmaceuticals Moat Score?

X4 Pharmaceuticals XFOR -2.93% 29 Moat Score is 4 as of Jun. 25, 2026. GuruFocus rates XFOR with a GF Score™ of 29/100. The stock has 7 warning signs investors should review. Among 1,405 Biotechnology companies, X4 Pharmaceuticals ranks better than 88.83% on this metric.

X4 Pharmaceuticals has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

X4 Pharmaceuticals has Narrow Moat: X4 Pharmaceuticals has a discernible but modest moat due to its valuable intellectual property and ongoing R&D efforts. However, it faces significant competition and lacks the scale or brand strength to achieve a stronger moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes X4 Pharmaceuticals might have Narrow Moat - Discernible but modest moat.

X4 Pharmaceuticals  (NAS:XFOR) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

X4 Pharmaceuticals Moat Score Related Terms

XFOR vs ZURA, LYEL, LXEO: Moat Score Comparison

For the Biotechnology subindustry, X4 Pharmaceuticals's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

X4 Pharmaceuticals Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, X4 Pharmaceuticals's Moat Score distribution charts can be found below:

* The bar in red indicates where X4 Pharmaceuticals's Moat Score falls into.


XFOR
29GF Score
X4 Pharmaceuticals Inc XFOR
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
X4 Pharmaceuticals (XFOR) has a Moat Score of 4 as of Jun. 25, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, X4 Pharmaceuticals ranks #157 out of 1405 companies in the Biotechnology industry, placing it in the top 11.2%.
Is X4 Pharmaceuticals' Moat Score too high?
X4 Pharmaceuticals' current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. X4 Pharmaceuticals' value of 4 is 100% above this industry median. Based on the distribution chart, X4 Pharmaceuticals ranks #157 out of 1405 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, X4 Pharmaceuticals has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does X4 Pharmaceuticals' Moat Score compare to ZURA and LYEL?
According to the Biotechnology industry distribution chart, X4 Pharmaceuticals ranks #157 out of 1405 companies for Moat Score. This places X4 Pharmaceuticals in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. X4 Pharmaceuticals' value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,405 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. X4 Pharmaceuticals's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. X4 Pharmaceuticals's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is X4 Pharmaceuticals stock overvalued right now?
X4 Pharmaceuticals (XFOR) has a current Moat Score of 4. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. X4 Pharmaceuticals' overall GF Score™ is 29/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For X4 Pharmaceuticals (XFOR), the current Moat Score is 4 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

X4 Pharmaceuticals Business Description

Address 61 North Beacon Street, 4th Floor, Boston, MA, USA, 02134
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
29GF Score

Get the complete analysis for XFOR

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.97
Price